Shots: The BT designation follows the P-IIb Trial in patients with IFD or probable invasive aspergillosis (IA) and either refractory disease, resistance, or intolerance to available agents The study resulted […]readmore
Tags : No
Shots: The P-III THEMIS study involves assessing of Brilinta (ticagrelor) + aspirin vs aspirin monothx in patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior myocardial […]readmore